ClinConnect ClinConnect Logo
Search / Trial NCT05550077

Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis

Launched by JIAOLIQUN · Sep 18, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Optical Coherence Tomography Intravascular Imaging Intracranial Atherosclerotic Stenosis Percutaneous Transluminal Angioplasty And Stenting

ClinConnect Summary

This clinical trial is studying the use of a special imaging technique called Optical Coherence Tomography (OCT) to help treat a condition known as intracranial atherosclerotic stenosis (ICAS). This condition occurs when the arteries in the brain become narrowed due to fatty deposits, which can lead to serious problems like strokes. The researchers want to find out how useful OCT is in guiding treatment for patients who have experienced symptoms related to this condition, like a transient ischemic attack (TIA) or a stroke.

To be eligible for this trial, participants should be between 65 and 74 years old and have symptoms linked to ICAS, with at least a 50% narrowing of one of the major arteries in the brain. However, individuals with certain conditions, like arteriovenous malformations or aneurysms, are not able to participate. If you join the study, you can expect to undergo assessments using OCT to help doctors understand your condition better and determine the best treatment options. This trial is currently recruiting participants, and it aims to improve care for people experiencing these serious health issues.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Symptomatic ICAS. Participants with ICAS with a transient ischaemic attack (TIA) or stroke attributable to the territory of the stenotic artery were defined as symptomatic. A TIA was defined as a transient episode of neurological dysfunction (focal weakness or language disturbance, transient monocular blindness, or required assistance in walking) caused by focal brain or retinal ischaemia that lasted for at least 10 minutes but resolved within 24 hours
  • Stenotic degree ≥ 50%, measured by digital subtraction angiography
  • The stenosis must located in at least one major intracranial artery (internal carotid artery, vertebral artery, middle cerebral artery, or basilar artery)
  • Exclusion Criteria:
  • Arteriovenous Malformation
  • Aneurysm

About Jiaoliqun

Jiaoliqun is a leading clinical trial sponsor dedicated to advancing medical research and innovation. With a strong focus on enhancing patient outcomes, the organization specializes in the design, management, and execution of clinical trials across various therapeutic areas. Committed to scientific integrity and regulatory compliance, Jiaoliqun collaborates with healthcare professionals, research institutions, and pharmaceutical companies to bring cutting-edge treatments from the laboratory to the marketplace. Their expertise in clinical development, combined with a patient-centered approach, positions them as a trusted partner in the pursuit of new therapies that address unmet medical needs.

Locations

Beijing, Beijing, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials